In this Section |
266976 Mammography screening rates and breast cancer mortality by race across SEER sitesTuesday, October 30, 2012
Background: Racial and geographic disparities in breast cancer mortality may be partially due to differing utilization of Medicare-reimbursed annual screening mammography which became effective in 1998. Objective: Determine the association between mammography screening rates and breast cancer mortality by race across SEER sites for time periods pre- and post-Medicare-reimbursement of annual screening mammography. Methods: Categorize mammography screening rates across SEER sites in 1995-1997 (time 1) and 2000-2002 (time 2) among black and white women ages 67-74 in the 5% SEER-Medicare non-cancer sample as low vs. high (approximate median split). Examine the association between mammography screening rates and 5-year breast cancer mortality among black and white cases diagnosed with non-metastatic disease in the same time periods. Results: After adjustment for stage at diagnosis and treatment, black women living in low mammography screening rate areas were at slightly reduced, but identical, risk of death in time 1 (hazard ratio [HR] 0.9, 95% confidence interval [CI] 0.5-1.6) and in time 2 (HR 0.9, 95% CI 0.5-1.6) relative to women living in areas with high mammography screening rates. In contrast, white women in low mammography screening rate areas were at no greater risk of death in time 1 (HR 1.0, 95% CI 0.9-1.3), but slightly reduced risk of death in time 2 (HR 0.8, 95% CI 0.6-1.0). Conclusions: There was little effect of low mammography screening rates on breast cancer mortality evidenced by slight reductions in risk of death, which appeared to be more pronounced among whites than among blacks in time 2.
Learning Areas:
Chronic disease management and preventionDiversity and culture Epidemiology Public health or related research Learning Objectives: Keywords: Breast Cancer Screening, Mortality
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: Lead author I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 4356.0: Cancer Screening and Prevention Poster Session
|